Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Hosted on MSN
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage
・Vor Biopharma shares surged over 40%after JPMorgan initiated coverage of the company. ・JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept. ・On ...
IRAEmpire has released a new and updated list of the best crypto IRA companies in the US to help consumers make better-informed decisions. DALLAS, TEXAS / ACCESS Newswire / December 26, 2025 / More Am ...
This is the type of soup that, at first glance, might seem a little…unexciting. But you’re underestimating the power of mushrooms, which do the heavy lifting. Saffron’s deep crimson threads add an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback